ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
ObsEva AnnouncesRelationshipwith Syneos Health to Commercialize Linzagolix
-Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids-
-Financing agreement with JGB Managementto fund the planned launch of linzagolix as well as other development and operational expenses-
-Amendment of Kissei exclusive license and supply agreement -
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland, October 13, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company dedicated to improving women’s reproductive health today announced a strategic relationship with Syneos Health® (Nasdaq:SYHN), the only fully integrated biopharmaceutical solutions organization, to commercialize linzagolix.
Linzagolix has the potential to be a best-in-class GnRH receptor antagonist for the treatment of uterine fibroids due to its efficacy and favorable tolerability profile.1,2,3 If approved, it would be the only GnRH antagonist for uterine fibroids with unique and flexible dosing options, as well as the first to offer a low dose option to address the needs of women who cannot or do not want to take hormones.1,4 Linzagolix is also being evaluated in an ongoing Phase 3 (EDELWEISS 3) study as a potential treatment for endometriosis-associated pain.
Brian O’Callaghan, CEO of ObsEva, commented, “We are thrilled to work with Syneos Health on the commercialization of linzagolix. With a leading women’s health sales force, Syneos Health is uniquely suited to support our goal of offering relief to women suffering from uterine fibroids. While traditional partnering arrangements with large pharma companies were considered, we believe that Syneos Health offers ObsEva the best option to maximize and maintain control, value and optionality for this important product. This Syneos Health relationship, together with the newly announced financing facility and revised Kissei license terms, provides ObsEva with a strong foundation to execute on its commercialization plans.”
“We are proud to work with ObsEva on the development of a critical treatment that has the potential to change the lives of women suffering from uterine fibroids,” said Michelle Keefe, President, Commercial Solutions at Syneos Health. “We are excited to support ObsEva in their launch utilizing our full-service commercial model including agency, field team, and operations support for linzagolix in both the U.S. and Europe.”
JGB Financing Agreement
ObsEva has also entered into a convertible note financing agreement with certain funds and accounts managed by JGB Management, Inc. which is structured to provide up to $135 million in borrowing capacity, available in nine tranches. The first tranche, for an initial $30 million, was funded at closing and used to retire the existing debt facility with Oxford Finance LLC. Notes issued in connection with each tranche will have a three-year term. All principal and interest will be convertible into ObsEva’s common shares at a price of $3.20 per share. In connection with each tranche, ObsEva will also issue warrants to purchase its common shares, including a warrant to purchase 1,634,877 common shares that was issued at the initial closing. The warrants will have an exercise price of $3.67 per share and a four year term from the date of issuance. Further information with respect to the debt facility will be provided in a Form 6-K filed by ObsEva with the Securities and Exchange Commission on October 13, 2021. Canaccord Genuity LLC acted as exclusive placement agent and financial advisor to ObsEva.
Kissei License and Supply Agreement
Finally, ObsEva’s exclusive license and supply agreement with Kissei for linzagolix has been amended so that first commercial sales milestones for the EU and the US will now be extended over a 5-year period. In addition, North American royalty payments have been lowered to tiered single digit royalties on net sales plus a supply price for the active pharmaceutical ingredient (API).
Linzagolix is a novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile1,2,3. Linzagolix has completed clinical trial development for the treatment of heavy menstrual bleeding associated with uterine fibroids and is currently in late-stage clinical development for the treatment of pain associated with endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product. Linzagolix is not currently approved anywhere in the world.
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 27,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
Cautionary Note Regarding Forward Looking Statements of ObsEva SA
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of and commercialization plans for ObsEva’s product candidates, including linzagolix, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities, and expectations regarding the use of funds from the financing agreement with JGB Management. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the ongoing novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with Securities and Exchange Commission (SEC) on March 5, 2021 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
CEO Office contact
+41 22 552 1550
+1 (617) 435-6602
1. Stewart E, ASRM 2020; Late-breaker abstract P-930
2. Al-Hendy A, NEJM 2021; 384:630-42
3. Schlaff W, NEJM 2020; 382:328-40
4. Bradley L, ASRM 2020; Late-breaker abstract P-931
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
trivago N.V.'s Third Quarter 2021 Earnings Release Scheduled for November 1, 202118.10.2021 15:30:00 CEST | Press release
DÜSSELDORF, GERMANY – October 18, 2021 - trivago N.V. (NASDAQ: TRVG) announced today that it will release its financial results for the third quarter for the period ended September 30, 2021 on Monday, November 1, 2021. On the same day, trivago N.V.'s management will conduct a webcast beginning at 1:15 PM CET / 8:15 AM EDT. These items will be available in the Investor Relations section of the company's website at https://ir.trivago.com/. A replay of the call is expected to be available for at least three months. About trivago N.V. trivago N.V. (NASDAQ: TRVG) is a global hotel and accommodation search platform. We are focused on reshaping the way travelers search for and compare different types of accommodations, such as hotels, vacation rentals and apartments, while enabling our advertisers to grow their businesses by providing them with access to a broad audience of travelers via our websites and apps. Our platform allows travelers to make informed decisions by personalizing their sea
Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists18.10.2021 14:00:00 CEST | Press release
~ Discovery efforts will focus on small molecules with differentiated clinical profiles to harness the broad potential of orexin agonism across different indications~ ~ First time Schrödinger is applying its computational platform in an orexin agonist setting enabled by Orexia’s structural biology capabilities ~ NEW YORK, BOSTON and LONDON, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Schrödinger (Nasdaq: SDGR) and Centessa Pharmaceuticals plc (“Centessa”) (Nasdaq: CNTA), together with subsidiary Orexia Therapeutics (“Orexia”), today announced an exclusive collaboration focused on the discovery of novel therapeutics targeting the orexin-2 receptor (OX2R), which is known to play a role in a broad spectrum of sleep disorders including narcolepsy. The collaboration provides Orexia with substantial access to Schrödinger’s entire computational platform as well as Schrödinger’s extensive expertise in ultra-large-scale deployment of its technology. Orexia will leverage Schrödinger’s computational platfo
Saniona completes submission of manufacturing data for Tesomet capsules to U.S. FDA18.10.2021 14:00:00 CEST | Press release
PRESS RELEASE 18October 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announcedthat it has completed the submission of all information previously requested by the U.S. Food and Drug Administration (FDA) regarding its chemistry, manufacturing and controls (CMC) programfor Tesomet capsules. With this submission completed, Saniona expects to be able to initiate its Phase 2b clinical trials for Tesomet before the end of 2021, as planned. There are multiple potential advantages to offering Tesomet as a capsule rather than a tablet to people living with Prader-Willi syndrome or hypothalamic obesity. Some of these individuals have a tendency to chew tablets, which could disrupt the effectiveness of the fixed-dose combination of Tesomet’s active ingredients. The Tesomet capsules contain the two active ingredients as microspheres, which are expected to minimize the impact of chewing or biting. Additionally, capsules are generally easier t
Saniona slutför inlämningen till FDA av tillverkningsdata för Tesometkapslar18.10.2021 14:00:00 CEST | Pressemelding
PRESSMEDDELANDE 18 oktober 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att alla uppgifter som det amerikanska läkemedelsverket FDA tidigare begärt in om bolagets program för kemi, tillverkning och kontroll (CMC) avseende Tesometkapslar nu har lämnats in. I och med att dessa uppgifter lämnats in förväntas Saniona att enligt plan kunna inleda kliniska studier i Fas 2b med Tesomet innan utgången av 2021. Det finns ett flertal möjliga fördelar med att erbjuda Tesomet som kapsel istället för tablett till personer som lever med Prader-Willis syndrom eller hypotalamisk fetma. Vissa av dessa drabbade individer tenderar att tugga sönder tabletter, vilket skulle kunna påverka effekten av den fasta doskombinationen av Tesomets aktiva substanser negativt. Tesometkapslarna innehåller de två aktiva substanserna i form av mikrosfärer, vilket väntas minimera påverkan från tuggande och bitande. Kapslar är dessutom i all
Prosafe SE and subsidiary company Prosafe Rigs Pte. Ltd. - Update on Financial Restructuring18.10.2021 13:30:03 CEST | Press release
Reference is made to the earlier information provided about the ongoing financial process with the lenders, the latest in: (a) a press release dated 13 October 2021 in relation to Prosafe SE's and Prosafe Rigs Pte Ltd's ("PRPL") applications for the Singapore Court to approve the Schemes agreed at the Scheme Meetings of the Scheme Creditors, in HC/OS 997/2021 and HC/OS 998/2021 (the "Sanction Applications"); and (b) a press release dated 14 October 2021 in relation to Westcon Yards AS' confirmation of their formal support of the Schemes. At the hearing of the Sanction Applications on 18 October 2021, the Singapore Court sanctioned the Schemes and permitted the insertion of a new clause 8.4 in the Schemes (as mentioned in the press release dated 13 October 2021). Prosafe SE and PRPL will proceed to lodge copies of the orders made by the Singapore Court with the Accounting and Corporate Regulatory Authority of Singapore. Prosafe SE wishes to thank all parties involved for their support o
Skyharbour Signs Option Agreement with Black Shield Metals Corp to Option 75% of the Mann Lake Uranium Project18.10.2021 13:00:00 CEST | Press release
VANCOUVER, British Columbia, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH)(OTCQB: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”) is pleased to announce that it has entered into an option agreement (the “Option Agreement”) with Black Shield Metals Corp. (CSE: BDX) (“Black Shield”) which provides Black Shield an earn-in option to acquire up to a 75% interest (the “Option”) in the Mann Lake Uranium Project (“Mann Lake” or the “Property”) located in the Athabasca Basin, Northern Saskatchewan, Canada. Mann Lake Project Location Map: https://skyharbourltd.com/_resources/SYH_Mann_Lake_Tenure.jpg Under the Option Agreement, Black Shield will contribute cash and exploration expenditure consideration totaling CAD $4,850,000 over a three-year period (“Project Consideration”). Of the Project Consideration, $850,000 will be in cash payments to Skyharbour and $4,000,000 will be in exploration expenditures on the project. Black Shield will also issue to Skyharbour
Hexagon Purus to join the ZeroCoaster project study, collaborating with leading partners to explore and develop the hydrogen value chain for maritime applications18.10.2021 13:00:00 CEST | Press release
Hexagon Purus joins the work package Zero Emission Compressed Hydrogen (ZECH) which is part of the ZeroCoaster project study coordinated by Vard, a major global ship design and shipbuilding company. This study aims to research, evaluate and present zero emission ship design solutions using alternative fuel systems. The ZeroCoaster represents coastal bulk cargo operations in Norway. Systems and component solutions revealed in the project are applicable for scaling and reconfiguring for other maritime applications. The project study is funded by The Research Council of Norway. One of the main objectives is to evaluate and challenge bunkering technologies and logistics operations, with a focus on safety, cost, and capacity. Hexagon Purus will contribute with its knowledge and expertise in storage and distribution of compressed hydrogen gas using Type 4 composite cylinder technology. Sharing knowledge to accelerate zero emission maritime solutions Norway has set a target to reduce emission